1月20日,CDE官网披露,百利天恒旗下核心管线iza-bren的第二项上市申请获得受理。该适应证用于治疗既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。 食管鳞癌的后线治疗是临床上面临的主要挑战。一旦一线免疫联合化疗方案失败,患者的治疗选择便急剧收窄。 1月20日,国家药品监督管理局药品审评中心(CDE)官网公示信息显示,由百利天恒自主研发的EGFR x HER3...
Source Link1月20日,CDE官网披露,百利天恒旗下核心管线iza-bren的第二项上市申请获得受理。该适应证用于治疗既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌。 食管鳞癌的后线治疗是临床上面临的主要挑战。一旦一线免疫联合化疗方案失败,患者的治疗选择便急剧收窄。 1月20日,国家药品监督管理局药品审评中心(CDE)官网公示信息显示,由百利天恒自主研发的EGFR x HER3...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.